Celanese Corporation (NYSE:CE) agreed to sell another 19% of the Nutrinova food-ingredients joint venture to Mitsui & Co., Ltd. for approximately $152 million in cash. The transaction, expected to close in the fourth quarter subject to customary conditions, will reduce the retained interest of Celanese Corporation (NYSE:CE) from 30% to 11%.
The interest being sold generated approximately $4 million of equity earnings in 2025. The consideration therefore equals about 38 times that contribution, suggesting Celanese Corporation is receiving a strong price for a noncore holding. The proceeds will reduce debt, fund upcoming maturities, and count toward the goal of Celanese Corporation to generate $1 billion from divestitures by the end of 2027.
Bull Case
The disclosed economics favor the sale. Paying $152 million for an interest that generated $4 million of equity earnings implies an earnings yield of only about 2.6% for the buyer. Celanese Corporation is exchanging a relatively small earnings contribution for immediate debt-repayment capacity and potential interest savings.
Celanese Corporation also retains 11% of Nutrinova, preserving some participation if the food-ingredients venture expands. Under the related diketene-facility arrangement, Nutrinova will cover the facility’s full purchase price and ongoing operating costs. Celanese Corporation has no funding obligation, limiting capital exposure while retaining an economic interest.
Combined with the completed $500 million Micromax divestiture, the latest transaction would bring the combined announced transaction values of the two deals to approximately $652 million. That would represent about 65% of the $1 billion divestiture objective.
Bear Case
The transaction is small relative to the balance-sheet challenge. Celanese Corporation ended 2025 with approximately $11.3 billion of company-defined non-GAAP net debt, defined as total debt less cash and cash equivalents. Celanese Corporation is targeting about $10 billion by the end of 2026 and below $9 billion by the end of 2027.
The reduction from the 2025 balance to the 2026 target is approximately $1.3 billion. If fully applied to debt, the $152 million proceeds would cover only about 12% of that reduction.
The 38-times comparison also uses one year of equity earnings rather than Nutrinova’s cash flow or long-term earnings potential. Reducing the interest to 11% sacrifices most future earnings and economic exposure, just as Nutrinova gains a new raw-material facility without requiring funding from Celanese Corporation.
Divestitures can accelerate deleveraging, but Celanese Corporation still depends on recurring cash generation. Celanese Corporation is targeting $700 million to $800 million of company-defined non-GAAP free cash flow in 2026. Celanese Corporation defines free cash flow as operating cash flow minus capital expenditures, adjusted for contributions from or distributions to noncontrolling-interest joint ventures.
Hedge Fund Sentiment
The filings available so far reflect positions held before Celanese Corporation reported the additional Nutrinova stake sale. Insider Monkey’s database showed 48 hedge funds holding Celanese Corporation at the end of 2Q2026, down from 49 funds three months earlier.
Conclusion
At the disclosed economics, deleveraging appears worth reducing the Nutrinova interest to 11%. The transaction advances the divestiture program without materially weakening current earnings. The broader investment case still depends on Celanese Corporation converting operating performance into free cash flow, completing additional asset sales and progressing toward its 2027 net-debt target.
READ NEXT: Main Street Capital’s (MAIN) Blowout Exit Fuels A Bigger Dividend and Here is Why Chevron (CVX) is a Favorite Among Hedge Funds
This article is originally published at Insider Monkey.
